Filing Details

Accession Number:
0001140361-17-010973
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-08 11:51:30
Reporting Period:
2017-03-06
Filing Date:
2017-03-08
Accepted Time:
2017-03-08 11:51:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1444380 Nevro Corp NVRO Surgical & Medical Instruments & Apparatus (3841) 562568057
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1622421 Michael Enxing C/O Nevro Corp.
1800 Bridge Parkway
Redwood City CA 94065
Vp Of Sales No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-03-06 37,000 $90.99 40,463 No 4 S Direct
Common Stock Acquisiton 2017-03-06 1,500 $3.60 41,963 No 4 M Direct
Common Stock Disposition 2017-03-06 800 $90.90 41,163 No 4 S Direct
Common Stock Disposition 2017-03-06 600 $92.35 40,563 No 4 S Direct
Common Stock Disposition 2017-03-06 100 $92.85 40,463 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-03-06 1,500 $0.00 1,500 $3.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,608 2022-12-17 No 4 M Direct
Footnotes
  1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  2. Includes 2,500 restricted stock units.
  3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.80 to $91.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.81 to $92.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. 100% of the shares subject to the option are fully vested and exercisable.